Abstract-An important research question in the study of the genetics of coronary artery disease (CAD) is whether information about genetic variation will improve our ability to predict CAD beyond established risk factors. This question is especially relevant to the goal of identifying young, asymptomatic adults with coronary atherosclerosis who would benefit most from interventions to reduce risk. Coronary artery calcification (CAC) detected by electron-beam computed tomography is a relatively new method for detecting coronary atherosclerosis in asymptomatic individuals that has been shown to be a more accurate indicator of coronary atherosclerosis in asymptomatic individuals than other noninvasive techniques. In a study of asymptomatic women (nϭ169) and men (nϭ160) between the ages of 20 and 59 representative of the Rochester, Minnesota population, we used logistic regression to ask whether the most common Apolipoprotein (Apo) E genotypes (⑀3/2, ⑀3/3, and ⑀4/3) predict the presence of CAC. The addition of information about ApoE genotypes to logistic models containing each separate risk factor did not improve prediction of CAC (PϾ0.10 in both women and men). However, there was significant evidence (PϽ0.10) that associations between variation in the probability of having CAC and variation in body mass index, plasma total cholesterol, and plasma ApoB in men and body mass index, plasma triglycerides, plasma ApoA1, and plasma ApoE in women were dependent on ApoE genotype. 
C oronary artery disease (CAD) is the primary cause of mortality in the United States today. 1 CAD is primarily detectable from clinical phenotypes such as myocardial infarction, angina, or sudden death due to coronary artery occlusion. Given the severity of these first disease symptoms, a major research goal has been to identify asymptomatic individuals with increased risk of coronary atherosclerosis so that treatment can be provided before they reach the clinical horizon. However, early diagnosis of asymptomatic individuals has been difficult because most noninvasive methods of coronary atherosclerosis detection (such as the treadmill exercise test or thallium scintigraphy) have low sensitivity in younger, asymptomatic individuals. 2 It has been known for many years that calcium deposits in coronary arteries are associated with atherosclerotic plaques. [3] [4] [5] Several studies 4, 6, 7 have found strong associations between CAD and the presence of coronary artery calcification (CAC) identified by autopsy, by computed tomography (CT), and by fluoroscopy. Recently, technologies have been developed to accurately detect CAC with electron beam CT. Recent studies 8, 9 have shown that CAC is a more sensitive marker for coronary atherosclerosis than other noninvasive techniques and that presence of CAC predicts future CAD morbidity and mortality in asymptomatic and symptomatic 10 adults.
During the past 10 years, genetics has become a central focus of research into the causes and predictors of common human diseases like CAD. One research focus has been on gaining knowledge about the genetic causes of common diseases that will direct our attention to the intermediate biochemical and physiological traits that may be used to detect those with increased risk or may serve as targets for early intervention to prevent disease. A second focus has been on identifying the genetic variations associated with interindividual variation in disease initiation, progression, or clinical severity that may provide more accurate prediction of disease than is provided by these intermediate traits. Genotypes at loci that influence interindividual variation in intermediate traits and are hypothesized to contribute to susceptibility of CAD, such as the one coding for apolipoprotein E (ApoE), may be better indicators of risk than intermediate traits because (1) an individual's genotype is more stable over time than intermediate traits, ( 2) an individual's genotype is not influenced by the disease process, and (3) each gene may have effects on multiple intermediate traits, some of which may be difficult to measure or inaccessible in vivo. On the other hand, it is also important to note that a genotype's influence on intermediate traits and on disease susceptibility may change over an individual's life cycle. For example, a genotype's influence may be modified by the disease process itself or the genotype may affect different sets of traits or disease outcomes in different environments at different ages.
For diseases with a single gene origin in which mapping between genetic variation and variation in presence of disease is expected to be Ϸ1:1, such genetic information is expected to provide both a basis for prediction of onset and severity of disease and for selection of interventions to prevent or treat disease. However, for common complex diseases like CAD, it is far from clear whether genetic variation will have utility for predicting or treating disease in the population at large. In general, it is expected that allelic variation in some CAD susceptibility genes will influence variation in risk of CAD that is not reflected by variation in the intermediate traits presently considered and variation in some intermediate traits will capture information about environmental effects and allelic variation in susceptibility genes that have not yet been measured. Consequently, an important research question in the study of the genetics of CAD is whether information about genetic variation will improve our ability to predict CAD beyond established risk factor traits. This question is especially relevant to the goal of identifying young, asymptomatic adults with increased risk of coronary atherosclerosis who would benefit most from interventions to reduce risk.
One of the best studied CAD susceptibility genes is ApoE. The common alleles of the ApoE gene (the ⑀2, ⑀3, and ⑀4) give rise to 6 genotypes; 3 of these genotypes (⑀3/2, ⑀3/3, and ⑀4/3) are common in most populations studied. ApoE genotypic information is hypothesized to confer CAD risk information because of its association with variation in lipid and apolipoprotein levels that are risk factors for CAD. [11] [12] [13] [14] [15] Evidence to support this hypothesis comes from findings that the relative frequency of the ⑀4 allele is elevated in high risk populations, 16, 17 increased in those individuals with CAD in many case-control and cross-sectional studies, 18 -21 and elevated in elderly men who died of CAD during a 5-year follow-up. 22 Although there is increasing evidence of ApoE as a CAD susceptibility gene, there have also been several studies that have reported no significant association between ApoE genotypes and risk of clinically defined symptomatic CAD. [23] [24] [25] [26] [27] Most ApoE genotype association studies have measured only the marginal, independent association between variation in ApoE genotype and variation in risk of CAD either before or after statistical adjustment for variation in other risk factors. The marginal effect of a genotype is a statistical measure of the impact of a particular genotype, averaged over all of the phenotypes in a particular sample that are associated with that particular genotype. However, we point out that the marginal effect of a genotype is only 1 way of looking at the influence of variation in a gene on variation in risk of disease or its associated risk factors. For example, it is becoming better understood that the influence of ApoE genotype on biochemical and physiological CAD risk factors is dependent on the levels of other risk factors such as age, body size, gender, and smoking status 14,15,28 -31 and that the relationship between intermediate biochemical and physiological traits is also dependent on ApoE genotype. 12, 32, 33 These studies suggest that variation in ApoE genotype may provide additional information about CAD risk beyond its marginal association when it is combined with knowledge about other risk factors. To investigate these issues, we considered 3 research questions in our study: (1) Does ApoE genotype predict the probability of having CAC when considered alone? (2) Does ApoE genotype predict the probability of having CAC after statistical adjustment for other CAD risk factors? and (3) Does ApoE genotype influence the statistical relationship between the CAD risk factors and the probability of having CAC?
Methods

Sample
As a part of the Rochester Family Heart Study, previously sampled individuals between the ages of 20 and 59 34, 35 were recruited to participate in a study of the epidemiology of CAC. Anyone who had undergone coronary surgery was not eligible to be in the CAC study. Further details of the sampling for this study are presented in Maher et al. 36 In the present study, we restricted the sample to those individuals who were measured for the ApoE genotype (as of January 1995) and had 1 of the 3 most common ApoE genotypes (ie, ⑀3/2, ⑀3/3, or ⑀4/3 genotypes). Six individuals with definite hypertension, 2 individuals with diabetes, 1 individual with a metal rod in his spine, 1 individual with symptomatic CAD, 1 individual with Klinefelter's syndrome, and 1 woman who reported that she was lactating were excluded from the present study because their conditions either substantially influence the measurement of CAC or influenced the risk factor levels that were measured in each individual. Women who reported they had taken exogenous hormones in the past month were not removed because they represent only 1 of a large number of environmental factors that influence normal variation in lipid and apolipoprotein levels.
Laboratory Methods
Age at examination (in years) was calculated using an individual's birth date. Height and weight were measured with a wall stadiometer and a beam balance. Body mass index (BMI) (kg/m 2 ) was used as a measure of body size. Systolic and diastolic blood pressure was measured in the right arm with a random-zero sphygmomanometer (Hawkslet & Sons, Ltd) at the Korotkoff phase I sound and the Korotkoff phase V sound, respectively. Three measures taken at least 2 minutes apart were averaged. Total cholesterol and triglyceride levels were measured by standard enzymatic methods (Beckman kits) as described by Kottke et al. 37 HDL cholesterol (HDL-C) was measured according to the method of Izzo et al. 38 Plasma levels of ApoA1, ApoB, and ApoE were measured by the use of radioimmunoassays. 37 The isoforms of the ApoE molecule were determined from frozen plasma samples by isoelectric focusing according to methods described in Kamboh et al. 39 The correspondence between ApoE genotypes assayed at the DNA level and plasma ApoE isoforms has been shown in a sample of unrelated individuals from the Rochester Family Heart Study. 40 Therefore, the ApoE isoforms phenotype were used to infer the ApoE genotypes referred to in the present study. Use of the term "ApoE genotype" also avoids confusion when referring to the plasma level of ApoE, which is also an ApoE phenotype.
Electron Beam CT Protocol
Details of the electron beam CT protocol are given in Maher et al. 36 Briefly, individuals were placed in a supine position on the scanning bench of the electron beam CT scanner (Imatron C-100, Imatron Inc). Forty contiguous 3-mm thick computed tomograms (transverse 2-dimensional images) were obtained from the root of the aorta to the apex of the heart. Scans were obtained with a 30-cm 2 field of view and transferred into a 512ϫ512 reconstruction matrix in which 1 pixelϭ0.343 mm. 2 Electrocardiographic triggering was used so that all images were obtained at late diastole when cardiac motion was minimal. Image acquisition time was 100 ms.
CT scan results were reviewed for technical quality and then scored by the use of information software by a single radiologic technologist who identified each focus of CAC, defined as an area of at least 2 adjacent pixels (0.69 mm 2 under field of view of 30) with a CT number Ͼ130 Hounsfield Units (HU) within the borders of a coronary artery, and marked it as a region of interest. Only 1 radiologic technologist was needed to score each examination because a study of interobserver and intraobserver reliability indicated it is not necessary for multiple observers to independently score a single examination. 41 In the present study, we defined presence of CAC as any calcific area Ն1.0 mm 2 in size with a CT number Ͼ130 HU in any of the 4 epicardial arteries. We used the 1.0 mm 2 definition of calcific area rather than a 0.69 mm 2 (2 pixel) definition to discriminate more fully between individuals who do and do not have reproducibly detectable CAC. This definition corresponded to a calcification score, as defined by Agaston, 42 of 1.0. In our study, there were no individuals with a calcific area Ͻ1 that had calcification scores Ͼ1.
Statistical Methods
All analyses were done in females and males separately. Unless otherwise indicated, the results from the statistical analyses discussed below were reported with 4 significance intervals (0.10ϾP Ն0.05, 0.05ϾPϾ0.01, 0.01ϾPՆ0.001, and PϽ0.001) to allow a continuum of liberal to conservative assessment of results by the reader. We chose to discuss the traditionally marginally significant results (0.10ϾPՆ0.05) in the text because in this relatively small preliminary study we are more concerned with type II errors than type I errors.
To address the first question in our study, logistic regression methods were used to assess whether there were significant difference among the 3 most common ApoE genotypes in predicting the probability of having CAC when considered alone. The effects of the ⑀3/2 and ⑀4/3 genotypes were modeled by coding design variables in such a way that the ⑀3/3 genotype represented the reference class (ie, the design variable for ⑀3/2 equaled 1 when ApoE genotype was ⑀3/2 and 0 otherwise; the same coding design was also used for the ⑀4/3 genotype). We used the likelihood ratio test to assess whether variation among these 3 ApoE genotypes was a significant predictor of variation in the probability of having CAC. Specifically, twice the natural logarithm of the ratio of the maximum of the likelihood of a logistic model with the ApoE genotype variables versus the maximum of the likelihood of a logistic model with an intercept only was taken to be approximately distributed as a 2 distribution with 2 degrees of freedom.
To address the second question of whether ApoE genotype was a significant predictor after considering established CAD risk factor traits, we compared the maximum of the likelihood of a logistic model that contained each CAD risk factor considered separately [(ie, Model 1: logit of P (CAC is present|risk factor)ϭ␣ϩ␤ (risk factor)] with the maximum of the likelihood of a logistic model containing both the particular CAD risk factor and ApoE genotype variation [(ie, Model 2: logit of P (CAC is present|risk factor, ApoE genotype)ϭ␣ϩ␤ 1 (risk factor)ϩ␤ 2 (⑀3/2)ϩ␤ 3 ⑀4/3)] by use of the likelihood ratio test. Twice the natural logarithm of the ratio of Model 2 to Model 1 is approximately distributed as a 2 distribution with 2 degrees of freedom.
To address the third question of whether variation in the ApoE genotype influenced the statistical relationship between any of the CAD risk factors and the probability of having CAC, we compared the maximum of the likelihood of a logistic model containing a single CAD risk factor and ApoE genotype (Model 2) versus the maximum of the likelihood of a logistic model containing a single CAD risk factor, ApoE genotype variables, and ApoE genotype variables by CAD risk factor interactions [(ie, Model 3: logit of P (CAC is present|risk factor, ApoE genotype, ApoE genotype ⅐ risk factor interactions)ϭ␣ϩ␤ 1 (risk factor)ϩ␤ 2 (⑀3/2)ϩ␤ 3 (⑀3/4)ϩ␤ 4 (⑀3/2 ⅐ risk factor)ϩ␤ 5 (⑀4/3 ⅐ risk factor)] by use of the likelihood ratio test. Twice the natural logarithm of the ratio of Model 3 to Model 2 is approximately distributed as a 2 distribution with 2 degrees of freedom. Interpretation of evidence for the ApoE genotype-dependent relationship between variation in the probability of having CAC and variation in risk factors assumes homogeneity of the range of risk factor values among genotypes. To test this assumption, we used a 2-sample t test and F test to test the null hypothesis of no mean and variance differences, respectively, in quantitative risk factors between 2 common genotypes with PϽ0.05 as the level of statistical significance. We considered 2 contrasts for each statistic, ⑀3/3ϭ⑀3/2 and ⑀3/3ϭ⑀4/3. Satterthwaite's correction for the t test was used when there was evidence of significant heterogeneity of variances between genotype classes. 43 
Results
Descriptive Statistics
In our sample of 169 women and 161 men between the ages of 20 and 60, we observed that 17% of women and 41% of men had CAC; the actual quantities of calcium observed in our sample ranged between 1.03 mm 2 and 281.8 mm. 2 In individuals under the age of 40, 14% of women (nϭ73) and 21% of men (nϭ82) had CAC. In individuals between the age of 40 and 60, 20% of women (nϭ96) and 62% of men (nϭ79) had CAC.
In Table 1 , we present the descriptive statistics for the distribution of CAD risk factors in each of the ApoE genotype and gender strata. In women, those with the ⑀3/2 genotype 
ApoE Gene Variation as a Predictor of CAC
To address our first research question, we used logistic regression to model the association between the variation in probability of having CAC and variation in ApoE genotype.
In Table 2 , we present the frequency distribution of ApoE genotypes and CAC. In women, 19.0% of ⑀3/2 individuals, 17.3% of ⑀3/3 individuals, and 16.0% of ⑀4/3 individuals had CAC. In men, 42.1% of ⑀3/2 individuals, 43.1% of ⑀3/3 individuals, and 35.9% of ⑀4/3 individuals had CAC. As expected given this frequency distribution, the logistic regression results presented in Table 3 indicate that there is no statistically significant association between variation in the probability of having CAC and variation in ApoE genotype. As a first step to address our second question of whether variation in ApoE genotype was a predictor after considering established CAD risk factors, we performed univariate logistic regressions on each of the CAD risk factors (denoted Model 1) and then compared Model 1 with a model containing only an intercept term. The results from these comparisons are presented in Column A of Tables 4 and 5 for women and men, respectively. When each of the CAD risk factors were considered alone, we found that age, BMI, systolic blood pressure (BP), diastolic BP, HDL-C, and ApoB were significant predictors of the presence of CAC in women. In men, all the CAD risk factors, except HDL-C and ApoA1, were significant predictors. The logistic regression coefficients indicate that increased levels of all the CAD risk factor traits, except ApoA1 and HDL-C, are associated with increased risk of CAC. The odds ratios associated with a 1 SD increase or decrease from the mean value of each risk factor are included in Tables 4 and 5 as an illustration of the magnitude and range of the observed risk factor association with presence of CAC in this sample. The second step in addressing our second question was to add information about variation in ApoE genotype to each logistic model containing a CAD risk factor (ie, Model 2). The results from comparing Model 1 and Model 2 are presented in Column B of Tables 4  and 5 in women and men, respectively. In both genders, in no case was there a significant improvement in the prediction of the probability of having CAC when information about variation in ApoE genotype was added.
To address our third question of whether ApoE genotype influences the relationship between variation in the probability of having CAC and variation in established CAD risk factors, we constructed logistic models containing each CAD risk factor, information about ApoE genotype, and interaction terms between variation in ApoE genotype and the particular CAD risk factor in the model (denoted Model 3). This model was compared with Model 2, which contained no interaction terms. The 2 from the likelihood ratio test between Model 3 and Model 2 are presented in Column C of Tables 4 and 5 for women and men, respectively. In women, ApoE genotype had a significant influence on the relationship between variation in the probability of having CAC and variation in BMI, triglycerides, ApoA1, and ApoE levels. In the Figure, we plot the influence of each ApoE genotype on the relationship between variation in the estimated probability of having CAC and variation in these coronary heart disease (CHD) risk factors in women. For BMI in women, the ⑀3/2 genotype was associated with a sharp increase in the estimated probability of having CAC for BMI's Ͼ25, whereas the ⑀4/3 and ⑀3/3 genotypes were similar in having more gradual increases for a given BMI level. For both plasma triglycerides and plasma ApoE levels in women, the ⑀4/3 genotype had the steepest increase in the estimated probability of having CAC for a given increase in risk factor level, whereas the ⑀3/3 genotype was associated with a more moderate increase and the ⑀3/2 was associated with a decrease in the probability of having CAC for a given increase in risk factor level. For ApoA1 in women, we found that the ⑀3/2 genotype had the sharpest decrease in the estimated probability of having CAC for a given increase in ApoA1 levels compared with the ⑀4/3 genotype that had a more gradual decrease and the ⑀3/3 genotype that had a slight increase. Overall, women with the ⑀3/2 genotype had a mixed combination of risk factor relationships with the probability of having CAC compared with women with the ⑀4/3 genotype. Specifically, women with the ⑀3/2 had an expected increase in probability of having CAC with increasing BMI and decreasing ApoA1 levels, but (counterintuitively) had a negative relationship between the probability of having CAC and triglyceride or ApoE levels. In contrast, women with the ⑀4/3 genotype had an expected increase in the probability of having CAC with increasing BMI, triglycerides, and ApoE levels and expected decreases in the probability of having CAC for increasing ApoA1 levels. In men, ApoE genotype had a significant influence on the relationship between variation in the probability of having CAC and variation in BMI, total cholesterol, and ApoB levels (Table 5 , Column C). In the Figure, we plot the influence of each ApoE genotype on the relationship between variation in the estimated probability of having CAC and variation in these risk factors in men. For BMI in men, the ⑀3/2 and ⑀4/3 genotypes had greater increases in the estimated probability of having CAC then the ⑀3/3 genotype. For both total cholesterol and ApoB in men, the ⑀3/3 and ⑀3/2 genotypes were associated with a significant positive relationship be- Model 1: logit of P (CAC is present|risk factor)ϭ␣ϩ␤ (risk factor). Model 2: logit of P (CAC is present|risk factor, ApoE)ϭ␣ϩ␤ 1 (risk factor)ϩ␤ 2 (⑀3/2)ϩ␤ 3 (⑀4/3). Model 3: logit of P (CAC is present|risk factor, ApoE, ApoE risk factor interactions)ϭ␣ϩ␤ 1 (risk factor)ϩ␤ 2 (⑀3/2)ϩ␤ 3 (⑀4/3)ϩ␤ 4 (⑀3/2 ⅐ risk factor)ϩ␤ 5 (⑀4/3 ⅐ risk factor).
*0.10ϾPՆ0.05, †0.05ϾPՆ0.01, ‡0.01ϾPՆ0.001, §PϽ0.001.
tween the probability of having CAC and these risk factors, whereas the probability of having CAC did not increase significantly with total cholesterol or ApoB levels in those with the ⑀4/3 genotype. Overall, men with the ⑀3/2 genotype and ⑀4/3 genotypes both had positive relationships between the probability of having CAC and BMI, total cholesterol, and ApoB levels, although in each of these instances men with the ⑀3/2 genotype had larger logistic regression coeffi-
The ApoE genotype dependent relationship between the estimated probability of having CAC and CAD risk factors.
cient estimates that indicate a stronger relationship between CAC and these intermediate traits in ⑀3/2 men versus ⑀4/3 men.
Discussion
Association of CAD With ApoE Genotype
Hundreds of studies have been carried out to evaluate the association between variation in risk of disease, variation in intermediate biochemical and physiological risk factors for disease, 16 and variation in the gene coding for the ApoE molecule. Strong associations between the frequency of CAD, ischemic heart disease (IHD), or CHD and the frequency of the ApoE genotypes carrying the ⑀4 allele have been found in case control studies, 18 -21,44 -46 in studies of special population subgroups, 16, 17, 47 and recently in a prospective study. 22 These results have raised expectations that the ApoE polymorphism may be useful in identifying asymptomatic individuals who are at higher risk of CAD. However, we also point out that there have also been numerous studies that have found no associations, [23] [24] [25] [26] [27] [28] or the relative frequency of the ⑀4 allele was actually lower in cases than in control subjects. 48 Other studies have found associations between the frequency of disease (CAD, IHD, and CHD) and the frequency of the ⑀2 allele in addition to an association with the frequency of the ⑀4 allele, 49,50 whereas 1 study only found an association between the presence of carotid artery disease and the presence of the ⑀2 allele. 51 These heterogeneous results among studies suggest that the influence of variation in the ApoE genotype on variation in disease susceptibility is likely to be heterogeneous within and between populations; that is, it may change over an individual's life time, it may be influenced by the disease process itself, and it may be different in different environments or genetic backgrounds. Our finding that the relationship between variation in established risk factor traits and variation in presence of CAC is influenced by variation in the ApoE genotype, even though we found no marginal statistical association, also supports the general conclusion that the influences of variation in the ApoE genotype on the variations in biochemical and physiological traits that determine risk of CAD may be biologically significant in some subgroups or populations but not in others.
To our knowledge, there have only been 2 studies that have investigated the association between variation in atherosclerotic lesions histologically measured in vitro in the coronary arteries or aorta 52, 53 and variation in the ApoE genotype. In both studies, arteries were removed at autopsy and evaluated to determine (1) the total percent of intimal surface involved in all atherosclerotic lesions (fatty streaks, fibrous plaques, complicated lesions, and calcified lesions) and (2) the total percent of intimal surface area involved in raised lesions (fibrous plaques, complicated lesions, and calcified lesions). Hixson et al 1991 52 observed no association between variation in either total percent surface area with atherosclerotic lesions or total percent surface area associated with raised lesions in the right coronary artery and variation in the ApoE genotype in white males 15 to 34 years of age who died of accidental causes. In both the thoracic and abdominal aorta, only variation in the total surface area associated with all atherosclerotic lesions, not raised lesions, was associated with variation in the ApoE genotype. In a sample of Alaskan natives 9 to 85 years in age who died of external causes (eg, accidents, homicide, suicide), again only variation in the total percent surface area defined by all atherosclerotic lesions, not raised lesions, was significantly associated with variation in the ApoE genotype. 53 In as much as the results of our study can be compared with the results of these studies (our measure of atherosclerotic lesions was restricted to calcified lesions), our findings are consistent with these studies in that we found no marginal association of calcified lesions with variation in the ApoE genotype. Taken together, studies of lesion phenotypes suggest that variation in initiation of CAD may be more strongly associated with variation in the ApoE genotype than the progression of CAD to the raised lesion status. 52, 53 ApoE Genotype Influences the Relationship Between Established Risk Factors and CAC Conceptually, our finding that variation in ApoE genotype influences the relationship between variation in the probability of having CAC and variation in established risk factors provides new insight into the complexity of the relationships between genome variability and variability in phenotypes that are measures of health. In basic terms, our findings further demonstrate that the mapping function between risk factor variation and interindividual variation in lifetime risk of progressive atherosclerosis is dependent of the context defined by an individual's genotype. This conclusion is both congruent with our understanding of the complexity of the etiology of CAD 54 that leads to the expectation that not everyone with high levels of atherogenic risk factors will necessarily develop disease, and it is incongruent with the commonly held belief that high levels of an atherogenic risk factor are invariably associated with increased risk. How could high levels of atherogenic risk factors not be associated with increased risk of CAD? Or conversely, how could low levels of atherogenic risk factors be associated with increased risk? Although we do not have knowledge of the biological mechanisms that might provide the answers to these particular questions, we have a basic understanding of how such events happen because we know that variation in disease susceptibility among individuals is a consequence of the interdependency 55 of the effects of susceptibility genotypes at many loci and the effects of different environmental exposures. 54 So, for instance, our findings that the ⑀4/3 genotype in women was associated with increased probability of having CAC at increased BMI, increased triglyceride levels, decreased Apo AI levels, and increased ApoE levels compared with the ⑀3/3 genotype ( Figure) are congruent with our understanding of CAD risk factors relationship with the risk of developing atherosclerosis. In contrast, the ⑀4/3 genotype in men was associated with increased probability of having CAC for increased BMI but not total cholesterol or ApoB levels compared with the ⑀3/3 genotype. Does this mean that the level of total cholesterol or ApoB in ⑀4/3 men is not a significant determinant of their probability of having CAC as much as other factors such as BMI, or other risk factors that were not genotype-gender dependent? We can only speculate that there are 2 underlying reasons for what we are seeing: (1) there are multiple other factors varying (age, smoking, etc) such that what we see with these 2-dimensional figures is a distortion of a multivariate reality where everything would be congruent if we could measure all the relevant variables for each individual in our sample, and (2) the variation in the ApoE molecules, represented by the genotype, has systemic, wide ranging effects on many biochemical and physiological interrelationships that are different in the preclinical and clinical manifestations of atherosclerosis. We know so little about the progression of atherosclerosis in free living individuals because up to now we have not had the ability to measure this stage of the atherosclerotic process. We note that our study only provides preliminary evidence for these ApoE genotype dependent effects and its inferences are limited because of our relatively small sample size and the relatively young age of our sample. Consequently, we can only speculate about the etiological underpinnings of the particular statistical associations between probability of having CAC and the particular ApoE genotype, gender, and risk factor level combinations that we observed in our study.
Uncertainty in the predictive ability of each particular risk factor (intermediate trait, susceptibility genotype, environmental factor) arises because each risk factor has a range of influences that changes according to the context defined by the states of the other intermediate traits, genotypes at other loci, and environmental factors. In other words, many individuals with a particular atherogenic risk factor level or a particular CAD susceptibility genotype may remain healthy because of compensatory effects determined by the states of their genetic or environmental backgrounds. In general, the distribution of the etiologies of common diseases such as CAD among individuals in the population at large is expected to involve only a small number of genetic or environmental factors with large marginal effects on risk of disease 54, 56 that are not dependent on other genetic and environmental factors. Variations in most causal agents, genetic and environmental, will have very small marginal effects in humankind at large; although, in a particular subsets of individuals, families, or populations, representing a particular subset of etiologies defined by the levels of other genetic or environmental agents, an agent may have a relatively large effect. Our findings demonstrate both of these points. First, we did not observe a statistically significant marginal association between variation in the probability of having CAC and variation in the ApoE genotype. Second, we illustrated ( Figure) that only at particular levels of intermediate risk factors is there an association between variation in the probability of having CAC and variation in the ApoE genotype. Thus, our study suggests that variation in a gene that has a small marginal association can still contribute to prediction of disease through interaction effects between interdependent agents and that we may miss a major portion of the genetic architecture of common diseases by assuming that only genotypes with large marginal effects acting in an independent and additive fashion on disease risk are important for prediction. In other words, whether the ⑀2 or ⑀4 allele is a risk factor for having CAC depends on its context, such as gender and biochemical risk factor level. This concept is not new in traditional animal and plant genetics in which the influence of a genotype is often viewed from 2 vantage points: (1) how it impacts the initial conditions underlying the development of the adult organism and (2) how it sets boundaries on the response to each shift in environment.
Our results also raise the question of how many biological models of disease will be necessary to explain the prevalence of CAD in the population at large-1 for each ApoE genotype and gender? At one end of the spectrum, we often assume that everyone has the same etiological processes operating to determine their disease risk and we seek to develop a single, "best" explanation in the statistical sense, model that relates agents involved in the causes of disease to prediction of risk of disease. We have gained much in terms of our general understanding of the causes of the risk of CAD from this approach. However, at the other end of the spectrum, we know that each individual is genetically and environmentally unique and therefore has their own specific, complex multifactorial etiology defined by the states of only a subset of all agents that are involved in determining the prevalence of disease in humankind in general. We suggest that the next generation of studies should focus on understanding the distribution of etiologies within and between populations and on identifying that subset of genotype-environment combinations that are associated with high risk of CAD in particular subsets of humankind.
